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Background: Data on efficacy of artemisinin-based combination therapy (ACT) to treat Plasmodium falciparum
during pregnancy in sub-Saharan Africa is scarce. A recent open label, randomized controlled trial in Mbarara,
Uganda demonstrated that artemether-lumefantrine (AL) is not inferior to quinine to treat uncomplicated malaria in
pregnancy. Haemozoin can persist in the placenta following clearance of parasites, however there is no data
whether ACT can influence the amount of haemozoin or the dynamics of haemozoin clearance.
Methods: Women attending antenatal clinics with weekly screening and positive blood smears by microscopy
were eligible to participate in the trial and were followed to delivery. Placental haemozoin deposition and
inflammation were assessed by histology. To determine whether AL was associated with increased haemozoin
clearance, population haemozoin clearance curves were calculated based on the longitudinal data.
Results: Of 152 women enrolled in each arm, there were 97 and 98 placental biopsies obtained in the AL and quinine
arms, respectively. AL was associated with decreased rates of moderate to high grade haemozoin deposition
(13.3% versus 25.8%), which remained significant after correcting for gravidity, time of infection, re-infection, and
parasitaemia. The amount of haemozoin proportionately decreased with the duration of time between treatment and
delivery and this decline was greater in the AL arm. Haemozoin was not detected in one third of biopsies and the
prevalence of inflammation was low, reflecting the efficacy of antenatal care with early detection and prompt
treatment of malaria.
Conclusions: Placental haemozoin deposition was decreased in the AL arm demonstrating a relationship between
pharmacological properties of drug to treat antenatal malaria and placental pathology at delivery. Histology may be
considered an informative outcome for clinical trials to evaluate malaria control in pregnancy.
Trial registration: REGISTRY: http://clinicaltrials.gov/ct2/show/NCT00495508
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Plasmodium falciparum malaria in pregnancy is a major
cause of morbidity and mortality for pregnant women
and their offspring [1]. Artesunate monotherapy is more
efficacious than quinine to treat severe malaria in Asian
adults [2] and African children [3] and is now the
recommended treatment [4]. The efficacy of artesunate
and artemisinin-based combination therapy (ACT) in
pregnancy has been well documented in Asia [5-8],
however data on efficacy of ACT to treat malaria during
pregnancy in sub-Saharan Africa is scarce [9-12]. The
WHO currently recommends ACT for treatment of
women in their second and third trimesters [4], yet
quinine remains widely used even though the seven-day
course is associated with more side effects and poor
compliance [9,13,14]. Quinine may remain first line
therapy due to greater availability, prescription habit
and possibly lower cost (although this might be untrue
thanks to increasing availability of subsidized ACT by
various programmes, e.g. Global Fund, President’s
Malaria Initiative, and World Bank).
In an antenatal cohort of women in Mbarara, Uganda,
a recent open label, randomized, non-inferiority trial of
artemether-lumefantrine (AL) versus quinine demon-
strated no difference in parasitological clearance rates
corrected for re-infection by PCR genotyping [9]. Al-
though there was no significant difference in clinical
outcome, there was a trend towards decreased rates of
low birth weight and pregnancy loss with AL [9].
The primary endpoints for treatment trials of malaria in
pregnancy are PCR-adjusted cure rates (day 42) [15] and ul-
timately birth weight, however no data exists whether
histopathology can be used to assess treatment efficacy.
Histopathological endpoints are well established for clinical
trials to treat chronic hepatitis B viral infection [16], to pre-
vent renal allograft rejection [17], and may also function as
surrogates for survival following chemotherapy [18]. During
malaria, placental histopathology is strongly associated with
birth outcomes [19-21], and has been utilized in a limited
number of preventative trials: improved pathology was seen
in two trials of intermittent presumptive therapy (IPT)
compared to placebo [22,23], whereas no histological differ-
ences were observed with vitamin A administration [24] or
in two trials examining differing IPT regimens [25,26].
The histological hallmarks of placental malaria infec-
tion are parasitized erythrocytes, intervillous inflamma-
tory infiltrate and haemozoin (malarial pigment)
deposition in fibrin (Figure 1). In a treatment trial the
majority of women are anticipated to be categorized
traditionally as “past” or “uninfected” based on the pres-
ence or absence of haemozoin in fibrin [27]. A scoring
system for placental malaria that includes semiquantita-
tive analysis of haemozoin deposition in fibrin was
developed to be appropriate for clinical trials with lowincidence of parasitaemia at delivery [19], and here was
applied to the current trial.
Artemisinin has a greater parasite reduction ratio than
quinine [28], and unlike quinine is active on early ring
stages. Both drugs are efficacious to treat uncomplicated
malaria in pregnancy [9], however AL was hypothesized
to lead to reduction of the cumulative parasite biomass
within the intervillous space of the placenta and thus re-
sult in reduced downstream pathology. Haemozoin de-
position and inflammation were assessed by histology for
the randomized controlled trial from Mbarara to deter-
mine whether AL versus quinine to treat uncomplicated
malaria in pregnancy was associated with reduced pla-
cental haemozoin and increased haemozoin clearance.Methods
Written informed consent was provided, and the study was
approved by four regulatory boards: the Faculty Research
Ethics Committee and the Institutional Review Board of
the Mbarara University of Science and Technology, the
Uganda National Committee for Science and Technology,
and the Comités de Protection des Personnes (Ile de
France XI, France). The use of specimens was approved by
the University of Washington Human Subjects Division.
Women attended antenatal clinics from 2006 to 2009
at the Mbarara University of Science and Technology
Hospital in Uganda, and were recruited to enter a cohort
involving weekly screenings by blood smear. This is an
area of meso-endemic transmission, with data for chil-
dren under five demonstrating a 43% prevalence of Plas-
modium falciparum determined by rapid diagnostic test
(RDT) and corrected by blood smear in 2004 declining
to 23% and 3% in rural and urban areas, respectively in
2010 [29]. Women with viable pregnancies >13 weeks
gestational age with positive blood smears by microscopy
either asymptomatic or symptomatic but without com-
plicated or severe malaria were eligible to participate in
the open label, randomized, non-inferiority efficacy trial
[9]. Women were directly observed to complete the
seven-day course of oral quinine (10 mg base per kg
bodyweight every 8 h for seven days) or the three-day
course of oral AL (fixed-dose combination of 20 mg and
120 mg at 0 h, 8 h, 24 h, 36 h, 48 h, and 60 h, given with
milk). Women with subsequent P. falciparum infection
were treated depending on study arm such that they
received the other study drug (quinine or AL). Women
with non-falciparum infections received chloroquine.
Women were followed in weekly antenatal clinics, with
rapid diagnostic tests followed by blood smears. Subse-
quent parasitaemia was genotyped as described [9].
Intermittent presumptive treatment (IPT) was discontin-
ued, and women were traced to their homes if they did
not attend clinic.
Figure 1 Key features of placental malaria. Haematoxylin and eosin stained placental sections from the Mbarara trial are shown at 600X. A)
Normal placental histology. B) Parasitized erythrocytes sequester in the intervillous space. C) Monocyte-macrophages accumulate and
phagocytose parasitized erythrocytes and haemozoin. D) Monocyte macrophages become enmeshed in fibrin and degenerate. E) Residual
haemozoin persists in fibrin following successful treatment.
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neutral buffered formalin, stored for a period of one to
four years, and were processed at University of Wash-
ington (UW) Medical Center Histology in 2010, with
one haematoxylin and eosin and one Giemsa stained
section per block. Formalin pigment was identified and
these samples were excluded from analysis of pigment
deposition or parasitaemia. Haemozoin deposition in fi-
brin and placental inflammation were scored on blinded
sections as previously described [19]. Briefly, parasitized
erythrocytes were identified by haemozoin and parasite
cytoplasm within an erythrocyte in the absence of for-
malin pigment or nearby debris, intervillous inflamma-
tion was categorically graded, and haemozoin within
fibrin was quantified as percentage of 600X high power
fields positive for haemozoin (Figure 2). Fields were
considered positive whether they contained single or
multiple granules of haemozoin. A cut off value for hae-
mozoin greater than 10% of high power fields (HPF) was
previously associated with birth weight reduction and
population distributions in cohorts from Tanzania and
the Thai-Burma border [19].
Clinical data included treatment arm, gravidity, day of
enrolment, level of parasitaemia, day of re-infection or
recrudescence, and haemoglobin at delivery. The totalnumber of antenatal visits prior to trial entry was not
available. Analysis of birth weight and anaemia will be
reported separately. Placental weights were not col-
lected. Categorical variables were analysed by chi-square
test or Fisher’s exact test. Continuous variables were
analysed using the unpaired t-test, except for gravidity,
parity and day of enrolment when the Mann–Whitney
test was used. Parasitaemia at enrolment and the% HPF
with haemozoin were log transformed prior to all ana-
lyses. Multivariate analysis was performed by ANOVA
or logistic regression for continuous and categorical
variables, respectively (Statview, SAS). Multivariate
models incorporated variables expected to contribute to
histological changes: duration between treatment and
delivery, gravidity, re-infection or recrudescence, and
parasitaemia at enrolment. Although there was a poten-
tial risk of confounding due to cross-over of study drug
to treat subsequent parasitaemia, re-infection was
included in the multivariate analysis because the infec-
tion at enrolment could have persisted from any time
during pregnancy prior to enrolment, whereas re-infec-
tion would have occurred between weekly screenings
and be promptly treated. Secondary analyses excluded
women with re-infection from the multivariate models,
and further included haemoglobin level at delivery,
Figure 2 Quantification of haemozoin deposition. Giemsa stained sections are shown at 200X. A) A selected field from the placenta of a
woman with infection at 162 days prior to delivery demonstrating a focus of haemozoin (inset, 600X), which was quantified as 2% of HPF. B) A
representative field from the placenta of a woman with infection at 77 days prior to delivery demonstrating heavy haemozoin deposition
quantified as 35% of HPF. Arrowheads: haemozoin deposits. HPF: 600X high power fields.
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Clearance curves were generated using Microsoft Excel
(Microsoft).Results
Of 304 women in the trial, histology was available for 97
in the quinine arm, and 98 in the AL arm (Figure 3).
There was no difference in maternal demographics or
day of enrolment based on whether histology was avail-
able (Table 1). Of women with histology available, there
was no difference by treatment arm for maternal demo-
graphics or infant outcome, although parasitaemia was
slightly higher at enrolment in the quinine arm (Table 2).Figure 3 Trial profile. The blue box contains the original CONSORT
trial flow chart, adapted from [9]. Placental histology was performed
as a secondary analysis. AL- Artemether-lumefantrine.Among women with histology, re-infection rates with P.
falciparum were similar between study arms: 12.2% (12/98)
in the AL arm, with two women having three separate add-
itional episodes each, and 13.4% (13/97) in the quinine arm
with one woman having two separate additional epi-
sodes. By PCR genotyping [9], there was a single docu-
mented P. falciparum recrudescence in each arm. For
non-P. falciparum infections (including Plasmodium
vivax, Plasmodium ovale, Plasmodium malariae), five
women in the AL arm had single-species infections and
one woman had mixed infection (with P. falciparum)
and one woman had one of each. In the quinine arm,
three women had single-species infections and one
woman had a mixed infection (with P. falciparum). A
single woman in the AL arm had taken sulphadoxine-
pyrimethamine for IPT prior to enrolment. Of the five
women in the clinical trial who did not complete the
seven-day course of quinine prior to delivery, three
women withdrew consent and two received rescue treat-
ment but no specimens were available.
Considering the extent of prolonged storage, there
were relatively few specimens with an obscuring amount
of formalin pigment (16/195, 8.2%), which was associated
with specimen dessication. Intervillous inflammation,
but not malaria pigment or parasitaemia, could be reli-
ably determined in specimens with obscuring formalin
pigment. In the remaining specimens, 65.9% (118/179)
had haemozoin, 8.2% (16/195) had intervillous inflam-
mation, and 7.3% (13/179) had parasitaemia by histology;
Table 2. Only a single case with high grade haemozoin
deposition (>40% HPF) was present (quinine arm) and
only a single case with massive intervillositis was present:
she was within the AL arm and was enrolled two days
prior to delivery of a stillborn infant. Of 13 women with
parasitized erythrocytes by histology, six were under ini-
tial treatment at time of delivery (two in the AL and four
in the quinine arm), three were placental blood smear
positive (two in the AL arm [both re-infections] and one
in the quinine arm [under initial treatment]), and the
Table 1 Demographic characteristics of women in the study separated by whether histology was available
With histology Without histology p
Age (y) Mean (SD); n 22.9 (5.0); 195 22.3 (4.7); 92 0.346
Parity Median [range]; n 1 [0-7]; 195 0 [0-5]; 91 0.295
Gravidity Median [range]; n 2 [1-8]; 195 2 [1-6]; 92 0.255
Birth weight (kg) Mean (SD); n 3.04 (0.47); 169 3.00 (0.41); 70 0.552
EGA enrolment (weeks) Mean (SD); n 23.8 (7.1); 194 22.5 (6.5); 92 0.144
Parasitaemia (per μL) Geometric mean [IQR]; n 1,546 [824-8,815]; 194 2,374 [451-6,453]; 92 0.092
EGA delivery (weeks) Mean (SD); n 39.2 (3.4); 192 39.1 (3.9); 91 0.861
Days between treatment and delivery Median [range]; n 104 [1-204]; 195 106 [1-201]; 92 0.604
Haemoglobin (g/dL) Mean (SD); n 12.0 (2.2); 169 11.5 (2.3); 79 0.069
AL- artemether-lumefantrine; EGA- estimated gestational age; IQR- interquartile range.
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with time of initial treatment ranging 70 to 100 days
prior to delivery (one of these women woman experi-
enced three separate re-infections, with the most recent
at 49 days prior to delivery). There was one blood smear
positive case (194 parasitized erythrocytes/μL) that did
not have parasitized erythrocytes detectable by histology;
she had been treated with quinine 68 days prior to deliv-
ery, and her delivery parasitaemia was confirmed as a re-
infection by PCR genotyping.
Among all women with histology, a moderate or
greater level of haemozoin deposition (>10% HPF)
was independently associated with the proximity of
the last malaria episode to delivery, lower gravidity,
and re-infection (p< 0.001, 0.022, and 0.014, respect-
ively by logistic regression). Parasitaemia at enrolment
significantly increased with proximity to delivery
(R = 0.285; p< 0.001 by linear regression), and was
increased in women with heavy haemozoin deposition
by univariate analysis (p = 0.001), however this associ-
ation was non-significant in the multivariate analysis
(p = 0.095). Re-infection was not associated with dif-
ferences in inflammation by histology, although the
sample size was small. There were two samples from
women who experienced PCR-confirmed recrudes-
cence (one in each arm), however histology wasTable 2 Demographic characteristics of women in the study s
available
Age (y) Mean (SD); n
Parity Median [range]; n
Gravidity Median [range]; n
Birth weight (kg) Mean (SD); n
EGA enrolment (weeks) Mean (SD); n
Parasitaemia (per μL) Geometric mean [IQR]; n
EGA delivery (weeks) Mean (SD); n
Days between treatment and delivery Median [range]; n
Haemoglobin (g/dL) Mean (SD); n
AL- artemether-lumefantrine; EGA- estimated gestational age; IQR – interquartile rancompromised in each by formalin pigment. Among
women who did and did not experience non-P. falcip-
arum infections, no pathological differences were
observed.
According to the treatment arm, there was no differ-
ence in the presence of formalin pigment, intervillous in-
flammation, parasitaemia, or absence of hemozoin by
histology. However, the proportion of cases with moder-
ate or greater levels of hemozoin (>10% HPF) were sig-
nificantly reduced in the AL arm by univariate analysis
(p = 0.031) and by logistic regression after correcting for
gravidity, day of enrolment, re-infection (yes/no), and
parasitaemia at enrolment (p = 0.028); Table 3. Results
were similar when numbers of re-infections were
included as a continuous variable. The effect of treat-
ment arm on haemozoin level remained significant after
the inclusion of haemoglobin at delivery (p = 0.013), but
was no longer significant after excluding the 22 women
who experienced re-infection in the multivariate analysis
(p = 0.171).
Haemozoin level when quantified as a continuous vari-
able (% HPF) was non-significantly decreased in the AL
arm (p= 0.090), and remained so after ANOVA
(p = 0.101). The longitudinal trial data allowed calcula-
tion of an estimated population haemozoin clearance
rate for women with malaria treated prior to delivery,eparated by treatment arm for those with histology
Quinine AL p
22.7 (4.6); 97 23.1 (5.3); 98 0.583
1 [0-6]; 97 1 [0-7]; 98 0.818
2 [1-7]; 97 2 [1-8]; 98 0.917
3.02 (0.50); 85 3.06 (0.45); 84 0.525
23.7 (6.7); 96 24.0 (7.6); 98 0.800
2,006 [205-5,029]; 97 1,191 [504-10,335]; 97 0.075
39.0 (3.8); 96 39.4 (2.9); 96 0.475
105 [1-192]; 97 91 [1-204]; 98 0.994
12.1 (2.4); 82 12.0 (1.9); 87 0.728
ge.
Table 3 Histological analysis by treatment arm
Quinine AL p p-adjusted
Formalin pigment n (%) 8/97 (8.2%) 8/98 (8.2%) 0.983 0.984
Haemozoin present n (%) 60/89 (67.4%) 58/90 (64.4%) 0.675 0.954
Haemozoin (% of HPF) Median [IQR]; n 3.3 [0-10.6]; 88 1.5 [0-5.7]; 90 0.090 0.101
Haemozoin >10% of HPF n (%) 23/89 (25.8%) 12/90 (13.3%) 0.031 0.028
Inflammation n (%) 8/97 (8.2%) 8/98 (8.2%) 0.999 0.974
Parasitized RBC n (%) 5/89 (5.6%) 8/90 (8.9%) 0.566 0.241
Adjusted p-values are corrected for day of enrolment, gravidity, parasitemia at enrolment and reinfection. AL- artemether-lumefantrine; HPF- high power fields.
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women with re-infection were excluded. The amount of
haemozoin increased with proximity of infection to de-
livery, however individual cases demonstrated much vari-
ation: for example one primigravid woman enrolled in
the month prior to delivery had no detectable placental
haemozoin deposition, whereas other primigravid
women had high levels. Stratified by treatment arm, the
magnitude of the curve was greater with quinine than
AL although the slopes were similar. Because primigra-
vid and secundigravid women had similar rates of low
birth weight, placental parasitized erythrocytes and in-
flammation (data not shown) they were included in the
same category for comparison to multigravid women
(Figure 4C). No significant relationship with treatment
arm was observed after excluding women with re-infec-
tion by ANOVA (p= 0.310), however a trend was
observed (p = 0.082) when gravidity was included as a
categorical variable, with initial clearance greatest in
multigravid women treated with AL.
This trial involving women undergoing weekly malaria
screenings since booking at antenatal clinics in Mbarara,
Uganda, establishes the sensitivity of histology to detect
haemozoin as a marker for “past” infection following
successful treatment (Table 4), which decreased from
86% to 28% with proximity of infection ranging from
one to six months prior to delivery. There was no differ-
ence by treatment arm. The maximum time between in-
fection and delivery that haemozoin could be detected
by placental histology in a woman without re-infectionFigure 4 Population haemozoin clearance curves. Estimated curves der
stratified by treatment arm, and C) treatment arm and gravidity. Excludingwas 162 days prior to delivery, at an estimated gesta-
tional age of 14 weeks at enrolment (quinine arm, shown
in Figure 2A).
Discussion
The overall results of the randomized controlled clinical trial
demonstrated that AL was not inferior to quinine with a
similar day 42 parasitological cure rate [9]. However AL was
associated with a trend towards decreased rates of low birth
weight and pregnancy loss. In the histological analysis, mod-
erate and high-grade haemozoin deposition was decreased in
the AL arm demonstrating a relationship between drugs used
to treat an antenatal malaria episode and placental pathology
at delivery.
Haemozoin deposits within fibrin are independently
associated with birth weight during placental malaria
[19], and they originate from monocyte-macrophages
that phagocytose parasite material, subsequently become
enmeshed in fibrin and degenerate. Monocyte-macro-
phages are a source of pro-inflammatory cytokines and
associated with poor outcomes [31,32]. Based on these
pathological data AL is hypothesized to be more clinic-
ally efficacious in pregnancy than quinine. Artemisinin
derivatives are active at ring stages and have greater
parasite reduction ratios compared to quinine [28] sug-
gesting that ACT clinical efficacy could be linked to a
greater reduction of sequestered mature-stage parasite
biomass during treatment. In the placenta, this reduced
sequestered parasite burden would result in less immune
cell activation and associated phagocytosis which wouldived from A) women in the trial (y =−4.44ln(x) + 9.71; R2 = 0.237), B)
22 women who experienced re-infection. HPF= high power fields.
Table 4 Sensitivity of histology to detect “past” infections
Months prior to delivery Haemozoin present; n (%)
1 19/22 (86.4%)
2 23/28 (82.1%)
3 25/38 (65.8%)
4 23/34 (67.6%)
5 23/34 (67.6%)
6 5/13 (27.8%)
7 0/5 (0%)
Haemozoin presence stratified by month of last Plasmodium falciparum
episode prior to delivery. Women who experienced re-infection are included in
the month that re-infection occurred.
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until delivery (Figure 5). Haemozoin is biologically active
and with a direct immunomodulatory effect in vitro [33],
however it is unknown whether haemozoin embedded
within placental fibrin exerts a biological effect during
pregnancy or whether it is simply an inert marker of cu-
mulative exposure to sequestered malaria parasites.
Haemozoin was not detected in approximately a third
of cases, similar to previous reports of prompt andFigure 5 Proposed model of increased ACT efficacy during
pregnancy. AL is active on early ring stages with a greater parasite
reduction ratio, limiting parasite sequestration. Quinine is only active
on mature parasites, which are sequestered in the placenta. Parasite
sequestration leads to mononuclear cell infiltration and risk of poor
pregnancy outcome. Haemozoin-laden macrophages become
enmeshed in fibrin resulting in haemozoin deposition that persists
until delivery. If women receive no or ineffective treatment,
sequestered parasites, inflammation and haemozoin deposits persist
until delivery.effective treatment of antenatal episodes resulting in no
residual histopathology [34]. Further, comparatively low
rates of intervillous inflammation and parasitaemia at de-
livery were observed in this trial, reflecting the efficacy of
frequent antenatal screenings with prompt treatment of
malaria in pregnancy. A much higher degree of path-
ology is seen in populations undergoing passive screen-
ing (consisting of IPT, bed net use and symptomatic
treatment) although a formal comparison cannot be
made across study sites due to differences in geography
and study design. HIV status was not assessed in the
trial, however considering that HIV is associated with
increased rates of chronic PM [35] and delayed acquisi-
tion of protective immunity [36], HIV would be hypothe-
sized to result in increased haemozoin deposition. The
prevalence of HIV infection in antenatal clinics was pre-
viously reported to be 13% in the Mbarara region [37].
All women in the histological trial completed the dir-
ectly observed seven-day course of quinine. Quinine is
known to be associated with poor compliance [13] and
data from this study would likely overestimate histo-
logical effectiveness of quinine in the population. In the
clinical trial seven of eight interrupted treatments were
in the quinine group [9]. Treatment failures in the AL
arm most likely reflected altered pharmacokinetics dur-
ing pregnancy of fixed dose lumefantrine [9] rather than
resistance to AL.
Although there was possibility of confounding due to
cross-over of study drug to treat re-infection, episodes of
re-infection were deemed sufficiency different from the
initial infection to include in the multivariate analyses.
Re-infection occurred between weekly screening visits
and was promptly treated whereas the infection at enrol-
ment could have persisted for any length of time during
pregnancy. In the absence of antenatal records available
for review, these women were likely not screened prior
to study enrolment. Exclusion of women with re-infec-
tion in secondary analyses demonstrated a non-signifi-
cant effect by treatment arm, perhaps due to insufficient
sample size.
The longitudinal trial design allowed for calculation of
estimated haemozoin clearance rates. These curves
hypothetically reflect the clearance of placental haemo-
zoin following successful treatment over the course of
gestation, analogous to parasite clearance curves from
peripheral blood [38]. Curves were affected by treatment
arm and parity, indicating a relationship between drug
efficacy and immunity. Haemozoin clearance would be
influenced by a combination of initial parasite burden,
haemozoin dissipation through placental growth and
perhaps biological clearance. Haemozoin levels increased
with proximity of infection to delivery. Placental growth
is most rapid in the third trimester where growth of the
chorionic villi is likely to dissipate haemozoin deposits
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small. Further, malaria in early gestation may limit pla-
cental growth [39], such that smaller placentas could be
hypothesized to have higher levels of hemozoin. Placen-
tal weights were not collected in this trial and ideally fu-
ture longitudinal studies would incorporate placental
weight with ultrasound assessment of growth and mea-
surements of placental haemozoin. Further, as a marker
for malaria exposure, data on the sensitivity to detect
“past” infections by histology (Table 4) would be useful
for sample size calculations for programmatic studies to
prevent or treat placental malaria prior to delivery.
As an alternative to histology, placental haemozoin
content was previously analysed by spectrophotometry
[40,41], and was similarly demonstrated to increase with
proximity of infection to delivery. However spectropho-
tometry would also detect haemozoin within intact para-
sitized erythrocytes and macrophages, potentially
confounding interpretation. For example, one subject in
this study had a low level of placental haemozoin depos-
ition (3.5% of HPF), consistent with effective treatment
two months prior to delivery, however at delivery there
was re-infection with 18% maternal erythrocytes parasi-
tized with haemozoin-containing mature forms which
would confound interpretation of treatment efficacy.
The specimens from this trial were processed in Seattle
using state of the art histology equipment. Pathology is a
crucial yet underfunded part of medical care in tropical
countries [42] and although histology is labour intensive,
prone to artefact and requires considerable expertise for
interpretation, investment in laboratory and training of
staff could strengthen local pathology services and gener-
ate long term benefit to the community. The placental
sections generated in this study were of excellent quality
and covered a wide range of pathology. This material
was used to generate training slide sets distributed
through the Malaria Research and Reference Reagent Re-
pository [43] that will hopefully contribute to training
and standardization in endemic areas. Improved local
pathology systems would facilitate the assessment of pla-
cental effects of malaria in an era of changing transmis-
sion and increasing drug resistance.
In conclusion, in the randomized controlled trial AL
was associated with lower rates of moderate to high-
grade haemozoin deposition compared to quinine for
treatment of uncomplicated malaria in pregnancy.
Decreased haemozoin deposition in the AL arm likely
reflects decreased cumulative sequestered parasite bio-
mass. The results support the WHO guidelines for
using ACT to treat malaria in the second and third tri-
mester of pregnancy. Placental histology is a useful and
sensitive tool to assess cumulative placental exposure to
malaria to evaluate malaria control policy and imple-
mentation in pregnancy.Abbreviations
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